Gene panel reconciliation services market seen reaching $2.38B by 2030

By AI, Created 4:31 PM UTC, May 18, 2026, /AGP/ – The gene panel reconciliation services market is forecast to nearly double to $2.38 billion by 2030 as precision medicine, genetic testing and AI-driven variant interpretation gain momentum. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Gene panel reconciliation services help labs compare genetic test panels, spot missing or overlapping genes and improve the consistency of clinical results. - Better standardization can support more accurate diagnoses and more personalized treatment decisions. - The market’s growth tracks with broader use of genetic testing, rare-disease screening and precision medicine.

What happened: - The Business Research Company released a report on the gene panel reconciliation services market on May 15, 2026. - The report estimates the market at $1.34 billion in 2025 and $1.5 billion in 2026. - The market is projected to reach $2.38 billion by 2030, rising at a 12.3% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period.

The details: - The report links near-term growth to precision medicine, artificial intelligence for variant interpretation, multi-omics integration and stricter regulation of genetic test standardization. - The report also points to stronger collaboration between diagnostic labs and research institutions as a growth factor. - Historical growth was driven by wider clinical genetic testing, higher rates of hereditary and rare diseases, broader use of next-generation sequencing and demand for precise variant classification. - The report says major trends will include more standardized genetic testing panels, cross-platform data harmonization, guideline-based variant interpretations, disease-specific gene panel optimization and regulatory-compliant reporting. - Gene panel reconciliation services are defined as the review and comparison of genetic test panels to ensure the genes analyzed are consistent and comprehensive. - The services are used to identify discrepancies, overlapping regions and missing genes across panels. - The report says that process supports reliability in diagnostic interpretation and clinical decision-making. - In February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022. - In October 2024, NHS England began a newborn screening program covering hundreds of babies for more than 200 rare genetic diseases, with plans to expand to as many as 100,000 babies nationwide. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The forecast suggests gene panel reconciliation is moving from a back-end lab function to a more central part of genetic testing infrastructure. - More AI use and tighter regulation both point to a market that may value accuracy, auditability and standardization over speed alone. - The split between North American leadership and Asia-Pacific growth signals a market that is already mature in some regions but still expanding quickly in others.

What’s next: - The report expects continued gains as labs adopt more harmonized panels and more formal interpretation standards. - Wider newborn screening and rare-disease testing could further increase demand for reconciliation services. - The market will likely keep expanding as diagnostic providers and research groups integrate more genomic data into clinical workflows.

The bottom line: - Gene panel reconciliation services are becoming a more important layer in genetic testing, and the market outlook points to sustained double-digit growth through 2030.